Q2 2019 Earnings Estimate for Synlogic Inc (SYBX) Issued By Wedbush

Synlogic Inc (NASDAQ:SYBX) – Stock analysts at Wedbush decreased their Q2 2019 earnings per share (EPS) estimates for shares of Synlogic in a note issued to investors on Monday, May 13th. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will earn ($0.52) per share for the quarter, down from their previous forecast of ($0.49). Wedbush also issued estimates for Synlogic’s Q3 2019 earnings at ($0.45) EPS, Q4 2019 earnings at ($0.45) EPS, FY2019 earnings at ($1.93) EPS, FY2020 earnings at ($1.91) EPS, FY2021 earnings at ($1.72) EPS, FY2022 earnings at ($1.27) EPS and FY2023 earnings at $0.91 EPS.

Synlogic (NASDAQ:SYBX) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.03. The firm had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.42 million. Synlogic had a negative net margin of 2,005.43% and a negative return on equity of 38.93%.

A number of other analysts also recently issued reports on SYBX. Zacks Investment Research raised shares of Synlogic from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a report on Wednesday. Chardan Capital set a $20.00 price objective on shares of Synlogic and gave the company a “buy” rating in a report on Friday, April 12th. Jefferies Financial Group assumed coverage on shares of Synlogic in a report on Tuesday, April 30th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, BTIG Research assumed coverage on shares of Synlogic in a report on Tuesday, February 12th. They issued a “buy” rating and a $22.00 price objective for the company. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Synlogic presently has a consensus rating of “Buy” and a consensus target price of $18.84.

NASDAQ SYBX opened at $8.30 on Thursday. The company has a quick ratio of 11.53, a current ratio of 11.53 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $210.73 million, a price-to-earnings ratio of -4.09 and a beta of 2.40. Synlogic has a 12-month low of $5.75 and a 12-month high of $14.59.

Several large investors have recently modified their holdings of SYBX. Legal & General Group Plc acquired a new position in shares of Synlogic in the 3rd quarter valued at approximately $33,000. Bank of Montreal Can raised its position in shares of Synlogic by 5,743.1% in the 1st quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 12,520 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Synlogic in the 1st quarter valued at approximately $114,000. Rhumbline Advisers raised its position in shares of Synlogic by 45.7% in the 4th quarter. Rhumbline Advisers now owns 21,753 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 6,820 shares in the last quarter. Finally, State of Wisconsin Investment Board raised its position in shares of Synlogic by 29.8% in the 1st quarter. State of Wisconsin Investment Board now owns 20,900 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 4,800 shares in the last quarter. Institutional investors own 81.12% of the company’s stock.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Featured Article: Commodities

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.